KAMADA » ALPHA-1 » ALPHA-1 IN KAMADA

ALPHA-1 IN KAMADA

AAT Intravenous: Glassia®

Kamada’s flagship product is Glassia®; an FDA approved intravenous Alpha-1 Antitrypsin (AAT), for the treatment of AAT Deficiency.
Glassia® is the first and only ready-to-use liquid AAT augmentation therapy for Alpha –1 Antitrypsin Deficiency (AATD).
Glassia® is FDA approved for chronic augmentation and maintenance therapy in individuals with emphysema due to alpha-1 antitrypsin (AAT) deficiency.
The Product is also sold in Israel, US, Brazil (Ventia®), Russia (Respikam®) and other countries.

AAT Inhaled

Kamada is at the forefront of clinical research with Alpha-1, as the company's second generation AAT product is an inhaled version. This product is already in advanced stages of clinical development in the EU for the treatment of Alpha-1 Deficiency.